BUY Blue Star — Sahi Research, 17 Sept 2026

bySahi ResearchHorizon: NA (inferred Swing (≤2wk))17 Sept 2026via Sahi Research Telegram

Entry₹1,517Stated

Target₹1,580

Stop loss₹1,480-2.44% risk

CMP₹1,531.89h ago

Active+0.98%+3.15%upside left 10d left

Follow Sahi Research for new calls(28% target hit, 87 closed calls)Get alerts Watch BLUESTARCO for new buy/sell callsGet alerts See 3 other Swing calls on BLUESTARCO

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 21 Sept, 12:37 am IST

2 supporting4 neutral4 opposing

Supports the BUY call (2)

MACD above its signal line — bullish momentum

Technicals · macd·20 Sept · today

2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·18 Sept · 2d ago

Neutral / worth noting (4)

Oracle Financial Services Software among 5 F&O stocks with sharp rise in futures open interest

NewsEt-Markets·17 Sept · 3d ago

Somerset-backed Cyrix Healthcare acquires Blue Star’s medtech business

NewsGoogle News·7 Sept · 2w ago

Cyrix Healthcare acquires Blue Star E&E's MedTech Solutions business

NewsGoogle News·5 Sept · 2w ago

Cyrix Healthcare acquires Blue Star E&E’s MedTech business

NewsGoogle News·4 Sept · 2w ago

Weighs against the BUY call (4)

Blue Star says Oman partner seeks annulment of arbitration award in Dubai court

NewsCnbc-Tv18·15 Sept · 5d ago

Blue Star sees no Q2 margin recovery as raw material costs bite

NewsGoogle News·8 Sept · 2w ago

Blue Star Share Price Falls 2.33%: Technicals, Valuation

NewsGoogle News·8 Sept · 2w ago

Blue Star Reports Ongoing Q2 Challenges Amid Input Price Inflation

NewsGoogle News·8 Sept · 2w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.